About Olivier

With an economics and sociology background, Olivier Maguet has been involved in the field of HIV/AIDS and Harm Reduction since the end of the ‘80s. In 2006, he joined Médecins du Monde/Doctors of the World as head of mission in Afghanistan to set up a Harm Reduction program in Kabul. From 2010 to 2016, he has been elected as Board Member as key referent for Harm Reduction in MdM network. Since 2014 he has been campaigning in MdM on drug pricing issue in OECD countries. Within his involvement, he has led two opposition procedures against Gilead’s sofosbuvir patents at European Patent Office – the first one having led to a core amendment of the prodrug patent in October 2016. He he’s now appointed as drug pricing campaign responsible for MdM. Alongside his voluntary involvement in MdM, Olivier Maguet is an independent consultant in the field of Harm Reduction and drug addiction.

This speaker will be presenting at the following session(s)

  • Options for countries without access to generic hepatitis medicines

    Ballroom 1

    Day: 2 November

    Time: 12:00

    Chairs: Ellen ‘t Hoen, University of Groningen, Netherlands and Dr. Massimo Ghidinelli, World Health Organization


    • Introduction to Intellectual Property.
      Ellen ‘t Hoen, University of Groningen, Netherlands
    • Patent opposition.
    • Olivier Maguet, Médecins du Monde
    • Malaysian strategy for access to HCV DAAs: road to compulsory licensing.
    • Shangeetha Thirumayni, Malaysian AIDs Council
    • How the interplay among scientific societies, medicines agency, and patients associations favoured drug price negotiation and allowed universal treatment of HCV: the Italian experience.
      Prof. Edoardo G. Giannini, University of Genoa, Italy
    • PAHO Strategic Fund - pooled procurement to improve access to high cost hepatitis medicines in commercial markets.
    • Juliana Vallini, Pan American Health Organization
    • Q & A session.